Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (31)

2024

  1. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)

    Clinical and Translational Oncology

  2. Discovery of a synthetic taiwaniaquinoid with potent in vitro and in vivo antitumor activity against breast cancer cells

    Biomedicine and Pharmacotherapy, Vol. 168

  3. Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis

    Breast, Vol. 69, pp. 342-348

  4. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  5. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041

  6. Oligometástasis en cáncer de mama: estrategias y perspectivas para el control local del tumor primario y de las metástasis

    Revisiones en Cancer, Vol. 37, Núm. 2, pp. 92-97

  7. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678

  8. TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression

    International Journal of Biological Sciences, Vol. 19, Núm. 1, pp. 204-224

2022

  1. Carcinoma localmente avanzado. Hormonoterapia neoadyuvante en cáncer de mama con expresión de receptores hormonales y HER2 negativo

    Revisiones en Cancer, Vol. 36, Núm. 6, pp. 295-303

  2. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study

    Seminars in Oncology, Vol. 48, Núm. 2, pp. 145-151

  2. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Immunophenotypic Conversion between Primary and Relapse Breast Cancer and its Effects on Survival

    Gynecologic and Obstetric Investigation, Vol. 85, Núm. 3, pp. 259-266

  2. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients

    Breast, Vol. 54, pp. 106-113

2019

  1. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  2. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

    Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 459-466

2018

  1. Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (Clinical and Translational Oncology, (2018), 20, 7, (862-869), 10.1007/s12094-017-1797-9)

    Clinical and Translational Oncology

  2. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869

  3. The role of exosomes on colorectal cancer: A review

    Journal of Gastroenterology and Hepatology (Australia), Vol. 33, Núm. 4, pp. 792-799